2021 | Abbvie Corporation | Rinvoq - 30 mg/tablet | upadacitinib | 02520893 | treatment of refractory moderate to severe atopic dermatitis | 01 Nov 2021 | Within Guidelines |
2021 | Amgen Canada | Kanjinti - 150 mg/vial | trastuzumab | 02518244 | Cancer | 07 Oct 2021 | Within Guidelines |
2021 | Amgen Canada Inc. | Amgevita - 20 mg/syringe | adalimumab | 02459310 | Rheumatoid arthritis | 19 Feb 2021 | Within Guidelines |
2021 | Amgen Canada Inc. | Amgevita - 40mg/auto-injector | adalimumab | 02459302 | Rheumatoid arthritis | 19 Feb 2021 | Within Guidelines |
2021 | Amgen Canada Inc. | Amgevita - 40mg/syringe | adalimumab | 02459299 | Rheumatoid arthritis | 19 Feb 2021 | Within Guidelines |
2021 | Amgen Canada Inc. | Riabni - 10 mg/mL | rituximab | 02513447 | Cancer | 21 Apr 2021 | Within Guidelines |
2021 | Astrazeneca Canada Inc. | Enhertu - 100 mg/vial | trastuzumab deruxtecan | 02514400 | Cancer | 08 Jul 2021 | Subject to Investigation |
2021 | Astrazeneca Canada Inc. | Fasenra Pen - 30 mg/dose | benralizumab | 02496135 | Eosinophilic asthma | 13 Jan 2021 | Within Guidelines |
2021 | Avir Pharma Inc. | Jorveza - 0.5 mg/tablet | budesonide | 02513854 | Eosinophilic esophagitis | 19 Oct 2021 | Under Review |
2021 | Avir Pharma Inc. | Jorveza - 1 mg/tablet | budesonide | 02493675 | Eosinophilic esophagitis | 07 Jan 2021 | Subject to Investigation |
2021 | Bayer Inc. | Verquvo - 10 mg/tablet | vericiguat | | Chronic Heart Failure | 19 May 2021 | Under Review |
2021 | Bayer Inc. | Verquvo - 2.5 mg/tablet | vericiguat | | Chronic Heart Failure | 19 May 2021 | Under Review |
2021 | Bayer Inc. | Verquvo - 5 mg/tablet | vericiguat | | Chronic Heart Failure | 19 May 2021 | Under Review |
2021 | Bayer Inc. | Xarelto - 1 mg/mL | rivaroxaban | 02510162 | Prevention of venous thromboembolic events | 11 Jun 2021 | Within Guidelines |
2021 | Bayer Inc. | Xarelto - 1 mg/mL | rivaroxaban | 02510170 | Prevention of venous thromboembolic events | 11 Jun 2021 | Within Guidelines |
2021 | BeiGene Ltd. | Brukinsa - 80 mg/capsule | zanubrutinib | 02512963 | Cancer | 01 Mar 2021 | Within Guidelines |
2021 | BGP Pharma ULC | Creon Minimicrospheres - 35000 unit/capsule | pancreatin | 02494639 | Pancreatic exocrine insufficiency | 10 Feb 2021 | Does Not Trigger Investigation |
2021 | Biomarin Pharmaceuticals Canada Inc. | Vimizim - 1 mg/mL | elosulfase alfa | 02427184 | Mucopolysaccharidosis type IVA | 27 Aug 2014 | Does Not Trigger Investigation |
2021 | Celegene Corporation | Onureg - 200 mg/tablet | azacitidine | 02510197 | Acute myeloid Leukemia | 25 Nov 2021 | Within Guidelines |
2021 | Celegene Corporation | Onureg - 300 mg/tablet | azacitidine | 02510200 | Acute myeloid Leukemia | 25 Nov 2021 | Within Guidelines |
2021 | CSL Behring Canada Inc. | Hizentra - 200 mg/mL | immune globulin subcutaneous (human) | 02498251 | Immune Deficiency | 13 May 2021 | Within Guidelines |
2021 | Dutch Ophthalmic Research Center (International) B.V. | Tissueblue - 0.25 mg/mL | brilliant blue g ophthalmic solution | 02510995 | Ophthalmic surgical dye | 30 Sep 2021 | Subject to Investigation |
2021 | Eli Lilly Canada | Emgality - 100 mg/mL | galcanezumab | 02505134 | Migraine | 11 Jan 2021 | Under Review |
2021 | Emd Sereno Canada | Tepmetko - 225 mg/tablet | tepotinib | 02516322 | Cancer | 07 Oct 2021 | Within Guidelines |
2021 | Gilead Sciences Canada Inc. | Trodelvy - 180 mg/vial | sacituzumab govitecan | 02520788 | Cancer | 22 Nov 2021 | Under Review |
2021 | Glaxosmithkline Inc. | Trelegy Elipta - 287.5 mcg/dose | fluticasone furoate/umeclidinium/vilanterol | 02515776 | Chronic obstructive pulmonary disease (COPD) | 13 Sep 2021 | Within Guidelines |
2021 | Hoffmann-La Roche Limited | Evrysdi - 0.75 mg/mL | risdiplam | 02514931 | Spinal Muscular Atrophy | 20 May 2021 | Within Guidelines |
2021 | Hoffmann-La Roche Limited | Phesgo 80/40 - 120 mg/mL | pertuzumab/trastuzumab | 02512912 | Cancer | 14 Apr 2021 | Subject to Investigation |
2021 | Hoffmann-La Roche Limited | Phesgo 60/60 - 120 mg/mL | pertuzumab/trastuzumab | 02512920 | Cancer | 14 Apr 2021 | Subject to Investigation |
2021 | Hoffmann-La Roche Limited | Polivy - 30 mg/vial | polatuzumab vedotin | 02515431 | Lymphoma | 26 Oct 2021 | Under Review |
2021 | Incyte Biosciences Canada Corporation | Minjuvi - 200 mg/vial | tafasitamab | 02518627 | Cancer | 29 July 2021 | Under Review |
2021 | Indivior Canada Ltd. | Suboxone 4/1 - 5 mg/film | buprenorphine/naloxone | 02502321 | Opioid Dependance | 17 Jun 2021 | Under Review |
2021 | Insmed Incorporated | Arikayce - 590 mg/vial | amikacin liposome inhalation suspension (ALIS) | | Antibiotic | 13 Jul 2021 | Subject to Investigation |
2021 | Janssen Inc. | Ponvory | ponesimod | 02515474 | Multiple sclerosis | 1 Nov 2021 | Within Guidelines |
2021 | Janssen Inc. | Ponvory - 20 mg/tablet | ponesimod | 02515482 | Multiple sclerosis | 1 Nov 2021 | Within Guidelines |
2021 | Janssen Inc. | Janssen COVID-19 Vaccine - 0.5 mL/dose | SARS-CoV-2 Vaccine [Ad26.COV2.S, recombinant] | 02513153 | COVID-19 | 12 Apr 2021 | Under Review |
2021 | Janssen Inc. | Opsynvi - 50 mg/tablet | macitentan/tadalafil | 02521083 | Pulmonary arterial hypertension | 25 Nov 2021 | Within Guidelines |
2021 | Kyowa Kirin Inc. | Poteligeo - 4 mg/mL | mogamulizumab | 02527715 | Cancer | 09 March 2021 | Under Review |
2021 | Medison Canada | Qinlock - 50 mg/tablet | ripretinib | 02500833 | Cancer | 10 Dec 2020 | Within Guidelines |
2021 | Medison Canada | Tavalisse - 100 mg/tablet | fostamatinib | 02508052 | Chronic Immune Thromocytopenia | 10 Dec 2020 | Within Guidelines |
2021 | Medison Canada | Tavalisse - 150 mg/tablet | fostamatinib | 02508060 | Chronic Immune Thromocytopenia | 10 Dec 2020 | Within Guidelines |
2021 | Novartis Pharmaceuticals Canada Inc. | Kesimpta - 20 mg/pen | ofatumumab | 02511355 | Multiple sclerosis | 08 Apr 2021 | Within Guidelines |
2021 | Organon Canada Inc | Hadlima - 40 mg/syringe | adalimumab | 02473097 | Rheumatoid arthritis | 19 Feb 2021 | Within Guidelines |
2021 | Organon Canada Inc | Hadlima Push Touch - 40 mg/auto injector | adalimumab | 02473100 | Rheumatoid arthritis | 19 Feb 2021 | Within Guidelines |
2021 | Paladin Labs Inc. | Xydalba - 500 mg/vial | dalbavancin | 02480522 | Antibiotic | 28 May 2021 | VCU |
2021 | Pfizer Canada | Braftovi - 75 mg/capsule | encorafenib | 02513099 | Cancer | 02 Nov 2021 | Within Guidelines |
2021 | Pfizer Canada ULC | Mektovi - 15 mg/tablet | binimetinib | 02513080 | Antineoplastic agent, protein kinase inhibitor | 02 Nov 2021 | Within Guidelines |
2021 | Sanofi-Aventis Canada | Dupixent - 300 mg/auto-injector | dupilumab | 02510049 | Atopic dermatitis | 27 May 2021 | Subject to Investigation |
2021 | Searchlight Pharma Inc. | Nextstellis 15/3 - 18 mg/tablet | estetrol monohydrate/drospirenone | 02513218 | Oral Contraceptive | 15 Jun 2021 | Under Review |
2021 | SpringWorks Therapeutics, Inc. | Nirogacestat - 10 mg/tablet | nirogacestat | | Cancer | 27 Apr 2021 | Under Review |
2021 | SpringWorks Therapeutics, Inc. | Nirogacestat - 100 mg/tablet | nirogacestat | | Cancer | 27 Apr 2021 | Under Review |
2021 | SpringWorks Therapeutics, Inc. | Nirogacestat - 50 mg/tablet | nirogacestat | | Cancer | 27 Apr 2021 | Under Review |
2021 | Sunovion Pharmaceuticals Canada Inc. | Cequa - 0.9 mg/mL | cyclosporine ophthalmic solution | 02512629 | keratoconjunctivitis sicca | 04 Nov 2021 | Within Guidelines |
2021 | Takeda Canada Inc. | Adynovate - 1000 IU/vial | antihemophilic Factor (Recombinant), PEGylated | 02498588 | Hemophilia A | 18 Aug 2021 | Within Guidelines |
2021 | Takeda Canada Inc. | Adynovate - 250 IU/vial | antihemophilic Factor (Recombinant), PEGylated | 02498537 | Hemophilia A | 19 Jul 2021 | Within Guidelines |
2021 | Takeda Canada Inc. | Adynovate - 500 IU/vial | antihemophilic Factor (Recombinant), PEGylated | 02498545 | Hemophilia A | 18 Aug 2021 | Within Guidelines |
2021 | Takeda Canada Inc. | Takhzyro - 150 mg/mL | lanadelumab | 02505614 | Cancer | 19 Jan 2021 | Within Guidelines |
2021 | Teva Canada Innovation G.P.-S.E.N.C. | Ajovy - 225 mg/auto-injector | fremanezumab | 02509474 | Migraine | 01 Apr 2021 | VCU |
2021 | Ultragenyx Pharmaceuticals Inc. | Dojolvi - 1000 mg/mL | triheptanoin | 02512556 | Lipid metabolism | 01 Apr 2021 | Within Guidelines |
2021 | Vertex Pharmaceuticals Canada Inc. | Kalydeco - 25 mg/pack | ivacaftor | 02519364 | Cancer | 01 Sep 2021 | Within Guidelines |